5 Key Takeaways

• 1

  Durability is a critical unmet need in wet age-related macular degeneration and diabetic macular edema treatment.

• 2

  Long-acting tyrosine kinase inhibitors may reduce treatment variability and improve long-term vision outcomes.

• 3

  Real-world patient adherence to anti-VEGF therapy is often lower due to barriers like transportation and caregiver strain.

• 4

  Fluctuations in retinal thickness are linked to worse visual outcomes and higher rates of fibrosis in patients.

• 5

  Long-acting therapies could enhance patient experience by reducing injection frequency and associated anxiety.